Clinical trials: Compensated Cirrhosis, active
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Hepatitis D
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Retrospective and prospective, pharmacological, multicentre, non-profit observational study. Consecutive patients with HDV-related compensated cirrhosis starting Bulevirtide 2 mg/day from September 2019 to December 2025 will be…
- Trial name
- SAVE-D (NCT06397859)
- Testing
- Bulevirtide
- Where
- Italy
- Volunteers
- 266 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
A total of 195 adult patients with biopsy-proven or clinically diagnosed metabolic dysfunction-associated with fatty liver disease(MAFLD)-related cirrhosis will be randomly divided into two arms.
- Trial name
- NCT06773221
- Testing
- Chiglitazar 64mg
- Where
- 4 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing Friendship Hospital
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
- Trial name
- NCT06419374
- Testing
- Pegozafermin
- Where
- 330 sites in United States, Argentina and 23 more
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Liver Cirrhosis
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- Trial name
- NCT07325526
- Testing
- BI 3802876
- Where
- 27 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
Liver Cirrhosis
Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).
- Trial name
- NCT04874428
- Testing
- Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cirrhosis, Portal Hypertension
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg).
- Conditions
- Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1
- Trial name
- B-REACH (NCT07797101)
- Testing
- Mazdutide injection
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Metabolic Dysfunction-associated Fatty Liver Cirrhosis
Fuzheng Huayu Tablets for Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Fuzheng Huayu Tablets in patients with metabolic dysfunction-associated fatty liver cirrhosis…
- Trial name
- NCT07663643
- Testing
- Fuzheng Huayu Tablets
- Volunteers
- 459 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
HBV-related Liver Cirrhosis
A Study on Peginterferon Alfa-2b Combined With NAs in Compensated HBV Cirrhosis
This study is a multicenter, randomized, prospective trial designed to evaluate the efficacy and safety of pegylated interferon α-2b (Peg-IFN-α2b) combined with nucleos(t)ide analogues (NAs) versus NAs monotherapy in patients…
- Trial name
- NCT07183293
- Testing
- Peginterferon alfa-2b combined with NAs, NAs
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Xiamen Humanity Hospital
Primary Biliary Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
The goal of this clinical study is to learn more about the study drug, seladelpar, and its effects on clinical outcomes in participants with primary biliary cholangitis (PBC) and compensated cirrhosis.
- Trial name
- AFFIRM (NCT06051617)
- Testing
- Seladelpar
- Where
- 218 sites in United States, Argentina and 27 more
- Volunteers
- 402 people
- Sponsor
- Gilead Sciences
Metabolic Dysfunction Associated Steatohepatitis
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study is open to adults who are at least 18 years old and have: A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or A confirmed liver disease called metabolic-associated steatohepatitis (MASH) BMI of 27…
- Trial name
- NCT06632457
- Testing
- Survodutide
- Where
- 447 sites in United States, Argentina and 35 more
- Volunteers
- 1,590 people
- Sponsor
- Boehringer Ingelheim
Cirrhosis
Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis
This phase III, randomized, double-blind, placebo-controlled, multi-center study seeks to test whether simvastatin, a statin usually used to lower cholesterol to prevent heart problems and strokes, can lower the risk of hepatic…
- Trial name
- SACRED (NCT03654053)
- Testing
- Simvastatin 40mg
- Where
- 11 sites in United States
- Volunteers
- 142 people
- Sponsor
- VA Office of Research and Development
Metabolic Dysfunction-associated Steatohepatitis
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
- Trial name
- NEBULA-1 (NCT07701993)
- Testing
- Efimosfermin alfa
- Where
- 30 sites in United States, Japan
- Volunteers
- 1,740 people
- Sponsor
- GlaxoSmithKline
NASH, Cirrhosis, Liver
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical…
- Trial name
- NCT05500222
- Testing
- Resmetirom
- Where
- 141 sites in United States, Belgium and 7 more
- Volunteers
- 845 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Metabolic Dysfunction-associated Steatohepatitis
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH.
- Trial name
- NEBULA-2 (NCT07704892)
- Testing
- Efimosfermin alfa
- Where
- 35 sites in United States, Japan
- Volunteers
- 380 people
- Sponsor
- GlaxoSmithKline
Liver Cirrhosis, Gastroesophageal Varices
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
This retrospective cross-sectional diagnostic study compared the diagnostic performance of ultrasound-measured spleen thickness (ST) and spleen diameter (SD) against esophagogastroduodenoscopy (EGD) for gastroesophageal varices…
- Trial name
- NCT07920744
- Testing
- spleen diameter, spleen thickness, esophagogastroduodenoscopy (EGD)
- Where
- China
- Volunteers
- 364 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Hepatitis B Virus Related Cirrhosis, Portal Hypertension Related to Cirrhosis
Hepatic and Splenic Microcirculatory Perfusion for Ruling Out High-Risk Varices in Patients With Hepatitis B-Related Cirrhosis
Background: Chronic hepatitis B (CHB)-related cirrhosis is a common cause of portal hypertension, which leads to the development of gastroesophageal varices (EGVs).
- Conditions
- Hepatitis B Virus Related Cirrhosis, Portal Hypertension Related to Cirrhosis, Esophagogastric Varices
- Trial name
- NCT07450651
- Volunteers
- 150 people
- Sponsor
- Beijing Friendship Hospital
Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis
Prognostic Model for MASLD Related Cirrhosis
This study enrolled 228 patients with MASLD-related cirrhosis confirmed by histopathology or clinical diagnosis. Follow-up was conducted every 3-6 months.
- Trial name
- NCT07082751
- Testing
- Lifestyle Guidance
- Where
- 9 sites in China
- Volunteers
- 228 people
- Sponsor
- Beijing Friendship Hospital
Hepatocellular Carcinoma (HCC), Cirrhosis
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
This study aims to investigate whether repeated 6-monthly screening for hepatocellular carcinoma (HCC) - called "HCC surveillance" - offered to selected patients with chronic liver disease can reduce HCC-related mortality by…
- Trial name
- BISHOP (NCT07469319)
- Testing
- Ultrasound of the liver and blood sample for alpha-fetoprotein
- Where
- 6 sites in Denmark
- Volunteers
- 617 people
- Sponsor
- University of Aarhus